Ocugen has completed 50% of enrollment for a phase 3 trial of OCU300 for the treatment of ocular redness and discomfort in patients with ocular graft-versus-host disease, according to a press release.
The double-masked, placebo-controlled 84-day trial will include 60 patients randomly assigned 2:1 to receive OCU300 (brimonidine 0.18% nanoemulsion) or placebo.
“The achievement of 50% enrollment is a key milestone towards the completion of this important phase 3 trial. [Ocular graft-versus-host disease] is a severe ocular autoimmune disease that occurs in up to 60% of allogeneic bone marrow
Uncategorized